Is pneumothorax a potential hazard of ribavirin therapy?

Ribavirin and Pneumothorax Risk

No—pneumothorax is not a recognized hazard of ribavirin therapy, and you should not withhold ribavirin solely due to concern for pneumothorax. 1, 2

• Evidence framing:
  • FDA label for inhaled ribavirin details adverse effects (teratogenicity, hemolysis with systemic use, bronchospasm/declining lung function with aerosol) but does not list pneumothorax as a risk or adverse reaction 1.
  • ECIL-4 guideline (hematology/HSCT) recommends aerosolized or systemic ribavirin for RSV and lists expected adverse events (bronchospasm, nausea, conjunctivitis, declining pulmonary function; hemolysis, LFT/renal abnormalities systemically), with no mention of pneumothorax 2.
  • Pneumothorax guidelines focus on disease management in CF/HIV/primary SP and do not implicate ribavirin as a cause; pneumothorax occurs due to underlying lung pathology, not antivirals 3, 4.

Algorithmic recommendation (prioritizing morbidity, mortality, QOL):

• If ribavirin is indicated (e.g., severe RSV in high-risk host):
  • Proceed with ribavirin.
  • Monitor for known toxicities:
    • Aerosolized: bronchospasm, decline in PFTs; ensure exposure precautions for pregnant staff 2.
    • Systemic: hemolysis, hepatic/renal dysfunction; adjust per renal function 2.
• If patient has existing pneumothorax:
  • Manage pneumothorax per guideline; this is unrelated to ribavirin use 3, 4.
  • Avoid BiPAP while pneumothorax persists to reduce morbidity/mortality 3.
• Pitfalls to avoid:
  • Attributing pneumothorax to ribavirin; no supportive evidence in drug label or high-quality guidelines 1, 2.
  • Missing bronchospasm from aerosolized ribavirin, which can worsen respiratory status; preplan bronchodilator support if reactive airways disease 2.